CA-LATTICEFLOW-AI
23.4.2024 09:01:32 CEST | Business Wire | Press release
LatticeFlow AI, the leading platform empowering Artificial Intelligence (AI) teams to build performant, safe, and trustworthy AI solutions, proudly announces that it has joined the U.S. AI Safety Institute Consortium (AISIC). LatticeFlow AI researchers will support Working Group #3, focusing on capability evaluations. Together with the National Institute of Standards & Technology (NIST) and other consortium members, LatticeFlow AI will support the development of methods, benchmarks, and testing environments that help organizations operationalize the practices outlined in NIST’s AI Risk Management Framework (RMF).
Dave Henry, SVP of Business Development at LatticeFlow AI, added: “AI safety programs are interdisciplinary in nature, requiring a broad range of management and technical skills to execute. The Consortium brings diverse experts together to create durable and innovative practices that promote trustworthy AI. We look forward to contributing our knowledge of AI model safety and collaborating on new approaches for scalable evaluations.”
Executive Demand for Trustworthy AI
Despite the impressive accuracy of AI models demonstrated in pilots and proof-of-concept projects, building AI solutions that perform reliably on real-world data remains an immense challenge. This affects both technical teams building and delivering AI solutions as well as management teams that need to quantify risks and approve AI solutions for use in business-critical operations. As a result, 85% of the models never make it into production, and out of those that do, 91% degrade over time.
“Unfortunately, high-value AI deployments are being delayed due to developer delay, insufficient good data governance and the inability to quantify possible risks associated with the use of their AI models,” stated Randolph Kahn Esq., President of Kahn Consulting Inc. “Consortiums such as AISIC can produce detailed guidelines and best practices, and when coupled with LatticeFlow AI’s technology, this can lead to a significant reduction of the time and cost required to complete thorough risk assessments and unlock the value of AI systems.”
The U.S. AI Safety Institute Consortium
AISIC was established by the U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) to contribute to the priority actions outlined in U.S. President Biden’s Executive Order on the Safe, Secure, and Trustworthy Development and Use of AI. These include developing red-teaming guidelines, technical assessment standards, and risk management practices, among other key elements to the development of trustworthy AI and its responsible use.
LatticeFlow AI's Contributions to Making AI Safe and Trustworthy
LatticeFlow AI’s association with AISIC follows a series of contributions made by the LatticeFlow AI team towards the goals outlined by AISIC and President Biden’s Executive Order. Since 2020, LatticeFlow AI has been an invited technical contributor to key AI Safety initiatives at the International Organization for Standardization, where it has actively contributed to the working group focusing on the development and standards for Trustworthy AI. Earlier this year, LatticeFlow AI hosted renowned AI leaders at the World Economic Forum’s AI House, gathering key figures in AI, including Gary Marcus (NYU), Apostol Vassilev (NIST), Kai Zenner (European Parliament), Matthias Bossardt (KPMG), Thomas Stauner (BMW), among other industry experts, to delve into the latest AI developments and discuss responsible AI adoption.
From Standards to Practice: First AI Assessment for a Leading Swiss Bank
Moving beyond the development of AI guidelines and standards, this year, LatticeFlow AI announced the first industry-pioneering technical AI Assessment for Migros Bank, a leading Swiss Bank, demonstrating how these AI standards are used in practice to mitigate risk and ensure regulatory compliance for business-critical AI solutions. The results of this assessment, alongside a concrete blueprint to implement AI governance and technical AI assessments at enterprises and governments, were presented at a dedicated event hosted at the ETH AI Center.
LatticeFlow AI’s Commitment to the U.S. and NIST’s AI Safety Institute Consortium
With its contributions to AISIC, LatticeFlow AI will continue its commitment to helping U.S. government agencies such as the U.S. Army ensure the safety and trustworthiness of mission-critical AI systems. Last year, White House officials announced LatticeFlow AI as the first-place winner in the “red teaming” AI Privacy Prize Challenge category. Subsequently, the company announced a strategic expansion towards the US and a three-year strategic engagement with the U.S. Army to build next-generation resilient AI solutions for mission-critical defense use cases.
"Joining AISIC will allow us to accelerate and broaden our impact by aligning our efforts towards ensuring AI trust and safety with global AI leaders, enterprises, and governments," said Petar Tsankov, Co-founder and CEO of LatticeFlow AI.
Interested in learning more?
- Watch the replay of our event on AI Governance & Audits: Navigating AI Risks and Compliance.
- Visit our web page to learn how to manage your AI model risk with comprehensive technical AI assessments.
- If you are interested in conducting an AI assessment, book a meeting with a LatticeFlow AI expert.
About LatticeFlow AI
LatticeFlow AI offers a cutting edge AI platform that empowers enterprise teams to build performant, safe, and trustworthy AI at scale. Our platform is designed to unlock the full value of AI by systematically addressing critical model and data issues through automated processes and intelligent workflows across your entire AI lifecycle.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240423153331/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
